Launch of PTRA Assay using Verici Dx's technology

Verici Dx plc

("Verici Dx" or the "Company") 

Successful completion of Thermo Fisher Scientific licensing and commercialisation agreement

Formal launch of Pre-Transplant Risk Assessment Assay using Verici's prognostic testing technology

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes that Thermo Fisher Scientific, the world leader in serving science, has announced the formal launch of its One Lambda™ Pre-Transplant Risk Assessment ("PTRA") Assay via its CLIA facility in Fishers, Indiana, utilizing the pre-transplant prognostic testing technology licensed by the Company to Thermo Fisher Scientific under the terms of a global licensing and commercialisation agreement announced on 15 November 2023 (the "Agreement").¹

Commenting on the milestones, Sara Barrington, CEO of Verici Dx, said:

"I am delighted to see that the PTRA Assay is being launched to the clinical community so swiftly and look forward to seeing how it can help transform patient outcomes. Together with the successful transfer of technology, this demonstrates our Company's commitment to timely and effective collaboration when executing these types of agreements." 

Tina Liedtky, President, Transplant Diagnostics, Thermo Fisher Scientific said:

"We're excited to introduce this innovative new tool that may help clinicians make more informed decisions about post-transplant management by providing information about patient risk of early acute rejection based on a patient's unique gene profile prior to transplant."

Enquiries:

Notes

1.     Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/62760

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.